Toward RNA interference‐based therapy for filovirus infections
Identifieur interne : 001588 ( Istex/Corpus ); précédent : 001587; suivant : 001589Toward RNA interference‐based therapy for filovirus infections
Auteurs : Kevin B. Spurgers ; Lynn S. Silvestri ; Kelly L. Warfield ; Sina BavariSource :
- Drug Development Research [ 0272-4391 ] ; 2009-06.
Abstract
Ebola (EBOV) and Marburg (MARV) viruses, of the family filoviridae, cause severe hemorrhagic fever in humans and nonhuman primates (NHPs) with mortality rates of up to 90%. Infection is thought to occur through mucous membranes or breaks in the skin after contact with infected animal tissue or body fluids of infected individuals. Beyond naturally occurring outbreaks, the potential use of these viruses in acts of bioterrorism remains a public health and national security concern. EBOV and MARV are classified as category A bioterrorism agents by the Centers for Disease Control and Prevention (CDC). To date, there are no licensed vaccines or therapeutics for filovirus infections. Major efforts are now under way to develop anti‐viral therapeutics that use the cellular RNA interference (RNAi) pathway. Small synthetic double‐stranded RNA oligonucleotides (siRNAs), or small hairpin RNAs (shRNAs) enter the RNAi pathway and guide the degradation of target mRNA transcripts with homologous sequence, for experimental or therapeutic benefit. Chemical modifications improve the in vivo stability of siRNAs and various strategies are being investigated to improve delivery. Importantly, siRNAs and shRNAs have been successfully used to inhibit virus replication in vitro, and in animal models. siRNAs as therapy for a variety of ailments have now moved into clinical trials. This review provides an overview of therapeutic siRNAs and details preclinical efforts to use these molecules as therapy for filovirus infections. Drug Dev Res 70:246–254, 2009. Published 2009 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/ddr.20302
Links to Exploration step
ISTEX:8F695DC3706B8D0E196621EAD7C011884B3CAB57Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Toward RNA interference‐based therapy for filovirus infections</title><author><name sortKey="Spurgers, Kevin B" sort="Spurgers, Kevin B" uniqKey="Spurgers K" first="Kevin B." last="Spurgers">Kevin B. Spurgers</name><affiliation><mods:affiliation>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</mods:affiliation></affiliation></author><author><name sortKey="Silvestri, Lynn S" sort="Silvestri, Lynn S" uniqKey="Silvestri L" first="Lynn S." last="Silvestri">Lynn S. Silvestri</name><affiliation><mods:affiliation>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</mods:affiliation></affiliation></author><author><name sortKey="Warfield, Kelly L" sort="Warfield, Kelly L" uniqKey="Warfield K" first="Kelly L." last="Warfield">Kelly L. Warfield</name><affiliation><mods:affiliation>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</mods:affiliation></affiliation></author><author><name sortKey="Bavari, Sina" sort="Bavari, Sina" uniqKey="Bavari S" first="Sina" last="Bavari">Sina Bavari</name><affiliation><mods:affiliation>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: sina.bavari@amedd.army.mil</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8F695DC3706B8D0E196621EAD7C011884B3CAB57</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/ddr.20302</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-KZH1CJ3C-S/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001588</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001588</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Toward RNA interference‐based therapy for filovirus infections</title><author><name sortKey="Spurgers, Kevin B" sort="Spurgers, Kevin B" uniqKey="Spurgers K" first="Kevin B." last="Spurgers">Kevin B. Spurgers</name><affiliation><mods:affiliation>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</mods:affiliation></affiliation></author><author><name sortKey="Silvestri, Lynn S" sort="Silvestri, Lynn S" uniqKey="Silvestri L" first="Lynn S." last="Silvestri">Lynn S. Silvestri</name><affiliation><mods:affiliation>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</mods:affiliation></affiliation></author><author><name sortKey="Warfield, Kelly L" sort="Warfield, Kelly L" uniqKey="Warfield K" first="Kelly L." last="Warfield">Kelly L. Warfield</name><affiliation><mods:affiliation>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</mods:affiliation></affiliation></author><author><name sortKey="Bavari, Sina" sort="Bavari, Sina" uniqKey="Bavari S" first="Sina" last="Bavari">Sina Bavari</name><affiliation><mods:affiliation>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: sina.bavari@amedd.army.mil</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Drug Development Research</title><title level="j" type="sub">Biodefense Countermeasure Development</title><title level="j" type="alt">DRUG DEVELOPMENT RESEARCH</title><idno type="ISSN">0272-4391</idno><idno type="eISSN">1098-2299</idno><imprint><biblScope unit="vol">70</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="246">246</biblScope><biblScope unit="page" to="254">254</biblScope><biblScope unit="page-count">9</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-06">2009-06</date></imprint><idno type="ISSN">0272-4391</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0272-4391</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Ebola (EBOV) and Marburg (MARV) viruses, of the family filoviridae, cause severe hemorrhagic fever in humans and nonhuman primates (NHPs) with mortality rates of up to 90%. Infection is thought to occur through mucous membranes or breaks in the skin after contact with infected animal tissue or body fluids of infected individuals. Beyond naturally occurring outbreaks, the potential use of these viruses in acts of bioterrorism remains a public health and national security concern. EBOV and MARV are classified as category A bioterrorism agents by the Centers for Disease Control and Prevention (CDC). To date, there are no licensed vaccines or therapeutics for filovirus infections. Major efforts are now under way to develop anti‐viral therapeutics that use the cellular RNA interference (RNAi) pathway. Small synthetic double‐stranded RNA oligonucleotides (siRNAs), or small hairpin RNAs (shRNAs) enter the RNAi pathway and guide the degradation of target mRNA transcripts with homologous sequence, for experimental or therapeutic benefit. Chemical modifications improve the in vivo stability of siRNAs and various strategies are being investigated to improve delivery. Importantly, siRNAs and shRNAs have been successfully used to inhibit virus replication in vitro, and in animal models. siRNAs as therapy for a variety of ailments have now moved into clinical trials. This review provides an overview of therapeutic siRNAs and details preclinical efforts to use these molecules as therapy for filovirus infections. Drug Dev Res 70:246–254, 2009. Published 2009 Wiley‐Liss, Inc.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>sirnas</json:string><json:string>ebov</json:string><json:string>filovirus</json:string><json:string>sirna</json:string><json:string>ebola</json:string><json:string>viral</json:string><json:string>rnai</json:string><json:string>ebola virus</json:string><json:string>pathway</json:string><json:string>virol</json:string><json:string>marburg</json:string><json:string>filovirus infection</json:string><json:string>geisbert</json:string><json:string>immune</json:string><json:string>replication</json:string><json:string>vero cell</json:string><json:string>nucleocapsid</json:string><json:string>shrnas</json:string><json:string>interferon</json:string><json:string>groseth</json:string><json:string>genome</json:string><json:string>antiviral</json:string><json:string>glycoprotein</json:string><json:string>spurgers</json:string><json:string>mirna</json:string><json:string>feldmann</json:string><json:string>virion</json:string><json:string>rnai pathway</json:string><json:string>virus infection</json:string><json:string>animal model</json:string><json:string>marv</json:string><json:string>transcription</json:string><json:string>clinical trial</json:string><json:string>mammalian cell</json:string><json:string>target gene</json:string><json:string>therapeutic benefit</json:string><json:string>virus replication</json:string><json:string>nonhuman primate</json:string><json:string>virus</json:string><json:string>infection</json:string><json:string>vero</json:string><json:string>biosafety level</json:string><json:string>filovirus outbreak</json:string><json:string>family filoviridae</json:string><json:string>mucous membrane</json:string><json:string>marv virion</json:string><json:string>small hairpin rna</json:string><json:string>animal tissue</json:string><json:string>disease control</json:string><json:string>ebola hemorrhagic fever</json:string><json:string>mortality rate</json:string><json:string>matrix protein</json:string><json:string>body fluid</json:string><json:string>virion assembly</json:string><json:string>grant sponsor</json:string><json:string>fort detrick</json:string><json:string>dendritic cell</json:string><json:string>bioterrorism agent</json:string><json:string>replication transcription</json:string><json:string>rnai inhibition</json:string><json:string>chemical modification</json:string><json:string>infectious disease</json:string><json:string>virus transcription</json:string><json:string>attractive target</json:string><json:string>virus membrane</json:string><json:string>state army medical research institute</json:string><json:string>cause severe hemorrhagic fever</json:string><json:string>sequence homology</json:string><json:string>viral vector</json:string><json:string>shrna expression</json:string><json:string>cell culture</json:string><json:string>sequence specificity</json:string><json:string>other virus</json:string><json:string>sirna treatment</json:string><json:string>gene function</json:string><json:string>virus production</json:string><json:string>marv infection</json:string><json:string>cell culture supernatant</json:string><json:string>western blot</json:string><json:string>plaque assay</json:string><json:string>infectious virus particle</json:string><json:string>marv virus production</json:string><json:string>marv gene</json:string><json:string>ebov infection</json:string><json:string>control animal</json:string><json:string>guinea pig</json:string><json:string>significant challenge</json:string><json:string>human clinical trial</json:string><json:string>animal efficacy rule</json:string><json:string>sina bavari</json:string><json:string>vascular permeability</json:string><json:string>pathol geisbert</json:string><json:string>gene</json:string></teeft></keywords><author><json:item><name>Kevin B. Spurgers</name><affiliations><json:string>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</json:string></affiliations></json:item><json:item><name>Lynn S. Silvestri</name><affiliations><json:string>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</json:string></affiliations></json:item><json:item><name>Kelly L. Warfield</name><affiliations><json:string>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</json:string></affiliations></json:item><json:item><name>Sina Bavari</name><affiliations><json:string>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</json:string><json:string>E-mail: sina.bavari@amedd.army.mil</json:string><json:string>Correspondence address: United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>siRNA</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>RNA interference</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>filovirus</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Ebola</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Marburg</value></json:item></subject><articleId><json:string>DDR20302</json:string></articleId><arkIstex>ark:/67375/WNG-KZH1CJ3C-S</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>Ebola (EBOV) and Marburg (MARV) viruses, of the family filoviridae, cause severe hemorrhagic fever in humans and nonhuman primates (NHPs) with mortality rates of up to 90%. Infection is thought to occur through mucous membranes or breaks in the skin after contact with infected animal tissue or body fluids of infected individuals. Beyond naturally occurring outbreaks, the potential use of these viruses in acts of bioterrorism remains a public health and national security concern. EBOV and MARV are classified as category A bioterrorism agents by the Centers for Disease Control and Prevention (CDC). To date, there are no licensed vaccines or therapeutics for filovirus infections. Major efforts are now under way to develop anti‐viral therapeutics that use the cellular RNA interference (RNAi) pathway. Small synthetic double‐stranded RNA oligonucleotides (siRNAs), or small hairpin RNAs (shRNAs) enter the RNAi pathway and guide the degradation of target mRNA transcripts with homologous sequence, for experimental or therapeutic benefit. Chemical modifications improve the in vivo stability of siRNAs and various strategies are being investigated to improve delivery. Importantly, siRNAs and shRNAs have been successfully used to inhibit virus replication in vitro, and in animal models. siRNAs as therapy for a variety of ailments have now moved into clinical trials. This review provides an overview of therapeutic siRNAs and details preclinical efforts to use these molecules as therapy for filovirus infections. Drug Dev Res 70:246–254, 2009. Published 2009 Wiley‐Liss, Inc.</abstract><qualityIndicators><refBibsNative>true</refBibsNative><abstractWordCount>234</abstractWordCount><abstractCharCount>1585</abstractCharCount><keywordCount>5</keywordCount><score>9.808</score><pdfWordCount>5153</pdfWordCount><pdfCharCount>34425</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>9</pdfPageCount><pdfPageSize>595.276 x 790.866 pts</pdfPageSize><pdfWordsPerPage>573</pdfWordsPerPage><pdfText>true</pdfText></qualityIndicators><title>Toward RNA interference‐based therapy for filovirus infections</title><genre><json:string>review-article</json:string></genre><host><title>Drug Development Research</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1098-2299</json:string></doi><issn><json:string>0272-4391</json:string></issn><eissn><json:string>1098-2299</json:string></eissn><publisherId><json:string>DDR</json:string></publisherId><volume>70</volume><issue>4</issue><pages><first>246</first><last>254</last><total>9</total></pages><genre><json:string>journal</json:string></genre><author><json:item><name>Lynne Gilfillan</name></json:item></author><subject><json:item><value>Research Overview</value></json:item><json:item><value>Research Overview</value></json:item></subject></host><namedEntities><unitex><date><json:string>2009</json:string></date><geogName></geogName><orgName><json:string>Proteomics Preclinical Research Preclinical Development Toxicology, Formulation Drug Delivery, Pharmacokinetics Clinical Development Phases I</json:string><json:string>Wiley-Liss, Inc.</json:string><json:string>Army Medical Research and Materiel Command</json:string><json:string>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD</json:string><json:string>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland</json:string><json:string>Wiley-Liss, Inc</json:string><json:string>USAMRMC</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Sina BavariÃ</json:string><json:string>Dev Res</json:string><json:string>Kelly L. War</json:string><json:string>Sina Bavari</json:string><json:string>Recent</json:string></persName><placeName><json:string>Marburg</json:string><json:string>America</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Haasnoot et al., 2007</json:string><json:string>Feng et al., 2007</json:string><json:string>Basler et al., 2003</json:string><json:string>Hartlieb and Weissenhorn, 2006</json:string><json:string>Mahanty and Bray, 2004</json:string><json:string>Bazhutin et al., 1992</json:string><json:string>Groseth et al., 2007a</json:string><json:string>Borden et al., 2007</json:string><json:string>Theriault et al., 2004</json:string><json:string>Muhlberger et al., 1999</json:string><json:string>Hoenen et al., 2006</json:string><json:string>Jaax et al., 1995</json:string><json:string>Geisbert et al., 2003a,b</json:string><json:string>Zampieri et al., 2007</json:string><json:string>Burnett et al., 2005</json:string><json:string>Leffel and Reed, 2004</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-KZH1CJ3C-S</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pharmacology & pharmacy</json:string><json:string>2 - chemistry, medicinal</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - pharmacology & pharmacy</json:string></scienceMetrix><scopus></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - pathologie infectieuse</json:string></inist></categories><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/ddr.20302</json:string></doi><id>8F695DC3706B8D0E196621EAD7C011884B3CAB57</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-KZH1CJ3C-S/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-KZH1CJ3C-S/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-KZH1CJ3C-S/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Toward RNA interference‐based therapy for filovirus infections</title><title level="a" type="short" xml:lang="en">ANTI‐FILOVIRUS siRNA DRUG DEVELOPMENT</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><licence>Published 2009 Wiley‐Liss, Inc.</licence></availability><date type="published" when="2009-06"></date></publicationStmt><notesStmt><note type="content-type" subtype="review-article" source="reviewArticle" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="review-article"><analytic><title level="a" type="main">Toward RNA interference‐based therapy for filovirus infections</title><title level="a" type="short" xml:lang="en">ANTI‐FILOVIRUS siRNA DRUG DEVELOPMENT</title><author xml:id="author-0000"><persName><forename type="first">Kevin B.</forename><surname>Spurgers</surname></persName><affiliation><orgName type="institution">United States Army Medical Research Institute of Infectious Diseases</orgName><address><addrLine>Fort Detrick</addrLine><addrLine>Frederick, Maryland 21702</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Lynn S.</forename><surname>Silvestri</surname></persName><affiliation><orgName type="institution">United States Army Medical Research Institute of Infectious Diseases</orgName><address><addrLine>Fort Detrick</addrLine><addrLine>Frederick, Maryland 21702</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Kelly L.</forename><surname>Warfield</surname></persName><affiliation><orgName type="institution">United States Army Medical Research Institute of Infectious Diseases</orgName><address><addrLine>Fort Detrick</addrLine><addrLine>Frederick, Maryland 21702</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0003" role="corresp"><persName><forename type="first">Sina</forename><surname>Bavari</surname></persName><email>sina.bavari@amedd.army.mil</email><affiliation><orgName type="institution">United States Army Medical Research Institute of Infectious Diseases</orgName><address><addrLine>Fort Detrick</addrLine><addrLine>Frederick, Maryland 21702</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><idno type="istex">8F695DC3706B8D0E196621EAD7C011884B3CAB57</idno><idno type="ark">ark:/67375/WNG-KZH1CJ3C-S</idno><idno type="DOI">10.1002/ddr.20302</idno><idno type="unit">DDR20302</idno><idno type="toTypesetVersion">file:DDR.DDR20302.pdf</idno></analytic><monogr><editor xml:id="editor-0000"><persName><forename type="first">Lynne</forename><surname>Gilfillan</surname></persName></editor><title level="j" type="main">Drug Development Research</title><title level="j" type="sub">Biodefense Countermeasure Development</title><title level="j" type="alt">DRUG DEVELOPMENT RESEARCH</title><idno type="pISSN">0272-4391</idno><idno type="eISSN">1098-2299</idno><idno type="book-DOI">10.1002/(ISSN)1098-2299</idno><idno type="book-part-DOI">10.1002/ddr.v70:4</idno><idno type="product">DDR</idno><imprint><biblScope unit="vol">70</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="246">246</biblScope><biblScope unit="page" to="254">254</biblScope><biblScope unit="page-count">9</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-06"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>Ebola (EBOV) and Marburg (MARV) viruses, of the family filoviridae, cause severe hemorrhagic fever in humans and nonhuman primates (NHPs) with mortality rates of up to 90%. Infection is thought to occur through mucous membranes or breaks in the skin after contact with infected animal tissue or body fluids of infected individuals. Beyond naturally occurring outbreaks, the potential use of these viruses in acts of bioterrorism remains a public health and national security concern. EBOV and MARV are classified as category A bioterrorism agents by the Centers for Disease Control and Prevention (CDC). To date, there are no licensed vaccines or therapeutics for filovirus infections. Major efforts are now under way to develop anti‐viral therapeutics that use the cellular RNA interference (RNAi) pathway. Small synthetic double‐stranded RNA oligonucleotides (siRNAs), or small hairpin RNAs (shRNAs) enter the RNAi pathway and guide the degradation of target mRNA transcripts with homologous sequence, for experimental or therapeutic benefit. Chemical modifications improve the in vivo stability of siRNAs and various strategies are being investigated to improve delivery. Importantly, siRNAs and shRNAs have been successfully used to inhibit virus replication in vitro, and in animal models. siRNAs as therapy for a variety of ailments have now moved into clinical trials. This review provides an overview of therapeutic siRNAs and details preclinical efforts to use these molecules as therapy for filovirus infections. Drug Dev Res 70:246–254, 2009. Published 2009 Wiley‐Liss, Inc.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="kwd1">siRNA</term><term xml:id="kwd2">RNA interference</term><term xml:id="kwd3">filovirus</term><term xml:id="kwd4">Ebola</term><term xml:id="kwd5">Marburg</term></keywords><keywords rend="articleCategory"><term>Research Overview</term></keywords><keywords rend="tocHeading1"><term>Research Overview</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-KZH1CJ3C-S/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1098-2299</doi><issn type="print">0272-4391</issn><issn type="electronic">1098-2299</issn><idGroup><id type="product" value="DDR"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="DRUG DEVELOPMENT RESEARCH">Drug Development Research</title><title type="short">Drug Dev. Res.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/ddr.v70:4</doi><titleGroup><title type="specialIssueTitle">Biodefense Countermeasure Development</title></titleGroup><numberingGroup><numbering type="journalVolume" number="70">70</numbering><numbering type="journalIssue">4</numbering></numberingGroup><creators><creator xml:id="sped1" creatorRole="sponsoringEditor"><personName><givenNames>Lynne</givenNames><familyName>Gilfillan</familyName></personName></creator></creators><coverDate startDate="2009-06">June 2009</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="5" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ddr.20302</doi><idGroup><id type="unit" value="DDR20302"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Research Overview</title><title type="tocHeading1">Research Overview</title></titleGroup><copyright ownership="restricted">Published 2009 Wiley‐Liss, Inc.</copyright><eventGroup><event type="firstOnline" date="2009-06-12"></event><event type="publishedOnlineFinalForm" date="2009-06-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:HeaderRef result:HeaderRef" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-17"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-16"></event></eventGroup><numberingGroup><numbering type="pageFirst">246</numbering><numbering type="pageLast">254</numbering></numberingGroup><correspondenceTo>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:DDR.DDR20302.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="59"></count></countGroup><titleGroup><title type="main" xml:lang="en">Toward RNA interference‐based therapy for filovirus infections<link href="#fn1"></link></title><title type="short" xml:lang="en">ANTI‐FILOVIRUS siRNA DRUG DEVELOPMENT</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Kevin B.</givenNames><familyName>Spurgers</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Lynn S.</givenNames><familyName>Silvestri</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Kelly L.</givenNames><familyName>Warfield</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Sina</givenNames><familyName>Bavari</familyName></personName><contactDetails><email>sina.bavari@amedd.army.mil</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">siRNA</keyword><keyword xml:id="kwd2">RNA interference</keyword><keyword xml:id="kwd3">filovirus</keyword><keyword xml:id="kwd4">Ebola</keyword><keyword xml:id="kwd5">Marburg</keyword></keywordGroup><fundingInfo><fundingAgency>Defense Threat Reduction Agency (DTRA)</fundingAgency><fundingNumber>4.10022_08_RD_B</fundingNumber></fundingInfo><fundingInfo><fundingAgency>Joint Science and Technology Office for Chemical and Biological Defense (JSTO‐CBD)</fundingAgency></fundingInfo><fundingInfo><fundingAgency>U.S. Army Medical Research and Materiel Command (USAMRMC)</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Ebola (EBOV) and Marburg (MARV) viruses, of the family filoviridae, cause severe hemorrhagic fever in humans and nonhuman primates (NHPs) with mortality rates of up to 90%. Infection is thought to occur through mucous membranes or breaks in the skin after contact with infected animal tissue or body fluids of infected individuals. Beyond naturally occurring outbreaks, the potential use of these viruses in acts of bioterrorism remains a public health and national security concern. EBOV and MARV are classified as category A bioterrorism agents by the Centers for Disease Control and Prevention (CDC). To date, there are no licensed vaccines or therapeutics for filovirus infections. Major efforts are now under way to develop anti‐viral therapeutics that use the cellular RNA interference (RNAi) pathway. Small synthetic double‐stranded RNA oligonucleotides (siRNAs), or small hairpin RNAs (shRNAs) enter the RNAi pathway and guide the degradation of target mRNA transcripts with homologous sequence, for experimental or therapeutic benefit. Chemical modifications improve the in vivo stability of siRNAs and various strategies are being investigated to improve delivery. Importantly, siRNAs and shRNAs have been successfully used to inhibit virus replication in vitro, and in animal models. siRNAs as therapy for a variety of ailments have now moved into clinical trials. This review provides an overview of therapeutic siRNAs and details preclinical efforts to use these molecules as therapy for filovirus infections. Drug Dev Res 70:246–254, 2009. Published 2009 Wiley‐Liss, Inc.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>This article is a US Government work and, as such, is in the public domain in the United States of America.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Toward RNA interference‐based therapy for filovirus infections</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>ANTI‐FILOVIRUS siRNA DRUG DEVELOPMENT</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Toward RNA interference‐based therapy for filovirus infections</title></titleInfo><name type="personal"><namePart type="given">Kevin B.</namePart><namePart type="family">Spurgers</namePart><affiliation>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lynn S.</namePart><namePart type="family">Silvestri</namePart><affiliation>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kelly L.</namePart><namePart type="family">Warfield</namePart><affiliation>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sina</namePart><namePart type="family">Bavari</namePart><affiliation>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702</affiliation><affiliation>E-mail: sina.bavari@amedd.army.mil</affiliation><affiliation>Correspondence address: United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-06</dateIssued><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">2</extent><extent unit="tables">2</extent><extent unit="references">59</extent></physicalDescription><abstract lang="en">Ebola (EBOV) and Marburg (MARV) viruses, of the family filoviridae, cause severe hemorrhagic fever in humans and nonhuman primates (NHPs) with mortality rates of up to 90%. Infection is thought to occur through mucous membranes or breaks in the skin after contact with infected animal tissue or body fluids of infected individuals. Beyond naturally occurring outbreaks, the potential use of these viruses in acts of bioterrorism remains a public health and national security concern. EBOV and MARV are classified as category A bioterrorism agents by the Centers for Disease Control and Prevention (CDC). To date, there are no licensed vaccines or therapeutics for filovirus infections. Major efforts are now under way to develop anti‐viral therapeutics that use the cellular RNA interference (RNAi) pathway. Small synthetic double‐stranded RNA oligonucleotides (siRNAs), or small hairpin RNAs (shRNAs) enter the RNAi pathway and guide the degradation of target mRNA transcripts with homologous sequence, for experimental or therapeutic benefit. Chemical modifications improve the in vivo stability of siRNAs and various strategies are being investigated to improve delivery. Importantly, siRNAs and shRNAs have been successfully used to inhibit virus replication in vitro, and in animal models. siRNAs as therapy for a variety of ailments have now moved into clinical trials. This review provides an overview of therapeutic siRNAs and details preclinical efforts to use these molecules as therapy for filovirus infections. Drug Dev Res 70:246–254, 2009. Published 2009 Wiley‐Liss, Inc.</abstract><note type="content">*This article is a US Government work and, as such, is in the public domain in the United States of America.</note><note type="funding">Defense Threat Reduction Agency (DTRA) - No. 4.10022_08_RD_B; </note><note type="funding">Joint Science and Technology Office for Chemical and Biological Defense (JSTO‐CBD)</note><note type="funding">U.S. Army Medical Research and Materiel Command (USAMRMC)</note><subject lang="en"><genre>keywords</genre><topic>siRNA</topic><topic>RNA interference</topic><topic>filovirus</topic><topic>Ebola</topic><topic>Marburg</topic></subject><relatedItem type="host"><titleInfo><title>Drug Development Research</title></titleInfo><titleInfo type="abbreviated"><title>Drug Dev. Res.</title></titleInfo><name type="personal"><namePart type="given">Lynne</namePart><namePart type="family">Gilfillan</namePart></name><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Research Overview</topic><topic>Research Overview</topic></subject><identifier type="ISSN">0272-4391</identifier><identifier type="eISSN">1098-2299</identifier><identifier type="DOI">10.1002/(ISSN)1098-2299</identifier><identifier type="PublisherID">DDR</identifier><part><date>2009</date><detail type="title"><title>Biodefense Countermeasure Development</title></detail><detail type="volume"><caption>vol.</caption><number>70</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>246</start><end>254</end><total>9</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus‐infected patients</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Baize</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EM</namePart><namePart type="family">Leroy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MC</namePart><namePart type="family">Georges‐Courbot</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Capron</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Lansoud‐Soukate</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Debre</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SP</namePart><namePart type="family">Fisher‐Hoch</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JB</namePart><namePart type="family">McCormick</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AJ.</namePart><namePart type="family">Georges</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baize S, Leroy EM, Georges‐Courbot MC, Capron M, Lansoud‐Soukate J, Debre P, Fisher‐Hoch SP, McCormick JB, Georges AJ. 1999. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus‐infected patients. Nat Med 5:423–426.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>423</start><end>426</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Med</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>423</start><end>426</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>VP24 of Marburg virus influences formation of infectious particles</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Bamberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Kolesnikova</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Moller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HD</namePart><namePart type="family">Klenk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Becker</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bamberg S, Kolesnikova L, Moller P, Klenk HD, Becker S. 2005. VP24 of Marburg virus influences formation of infectious particles. J Virol 79:13421–13433.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>13421</start><end>13433</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>13421</start><end>13433</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>MicroRNAs: genomics, biogenesis, mechanism, and function</title></titleInfo><name type="personal"><namePart type="given">DP.</namePart><namePart type="family">Bartel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>281</start><end>297</end></extent></part><relatedItem type="host"><titleInfo><title>Cell</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>281</start><end>297</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3</title></titleInfo><name type="personal"><namePart type="given">CF</namePart><namePart type="family">Basler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Mikulasova</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Martinez‐Sobrido</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Paragas</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Muhlberger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Bray</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HD</namePart><namePart type="family">Klenk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Palese</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Garcia‐Sastre</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Basler CF, Mikulasova A, Martinez‐Sobrido L, Paragas J, Muhlberger E, Bray M, Klenk HD, Palese P, Garcia‐Sastre A. 2003. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 77:7945–7956.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>77</number></detail><extent unit="pages"><start>7945</start><end>7956</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>77</number></detail><extent unit="pages"><start>7945</start><end>7956</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys</title></titleInfo><name type="personal"><namePart type="given">NB</namePart><namePart type="family">Bazhutin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EF</namePart><namePart type="family">Belanov</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VA</namePart><namePart type="family">Spiridonov</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AV</namePart><namePart type="family">Voitenko</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NA</namePart><namePart type="family">Krivenchuk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SA</namePart><namePart type="family">Krotov</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NI</namePart><namePart type="family">Omel'chenko</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Tereshchenko</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VV.</namePart><namePart type="family">Khomichev</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bazhutin NB, Belanov EF, Spiridonov VA, Voitenko AV, Krivenchuk NA, Krotov SA, Omel'chenko NI, Tereshchenko A, Khomichev VV. 1992. The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys. Vopr Virusol 37:153–156.</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>153</start><end>156</end></extent></part><relatedItem type="host"><titleInfo><title>Vopr Virusol</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>153</start><end>156</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Interferons at age 50: past, current and future impact on biomedicine</title></titleInfo><name type="personal"><namePart type="given">EC</namePart><namePart type="family">Borden</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GC</namePart><namePart type="family">Sen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Uze</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RH</namePart><namePart type="family">Silverman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RM</namePart><namePart type="family">Ransohoff</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GR</namePart><namePart type="family">Foster</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GR.</namePart><namePart type="family">Stark</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6:975–990.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>975</start><end>990</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Rev Drug Discov</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>975</start><end>990</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>The evolving field of biodefence: therapeutic developments and diagnostics</title></titleInfo><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Burnett</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EA</namePart><namePart type="family">Henchal</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AL</namePart><namePart type="family">Schmaljohn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Bavari</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Burnett JC, Henchal EA, Schmaljohn AL, Bavari S. 2005. The evolving field of biodefence: therapeutic developments and diagnostics. Nat Rev Drug Discov 4:281–297.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>281</start><end>297</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Rev Drug Discov</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>281</start><end>297</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Human immunodeficiency virus type 1 escapes from RNA interference‐mediated inhibition</title></titleInfo><name type="personal"><namePart type="given">AT</namePart><namePart type="family">Das</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TR</namePart><namePart type="family">Brummelkamp</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EM</namePart><namePart type="family">Westerhout</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Vink</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Madiredjo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Bernards</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Berkhout</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R, Berkhout B. 2004. Human immunodeficiency virus type 1 escapes from RNA interference‐mediated inhibition. J Virol 78:2601–2605.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>2601</start><end>2605</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>2601</start><end>2605</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Interfering with disease: a progress report on siRNA‐based therapeutics</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">de Fougerolles</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HP</namePart><namePart type="family">Vornlocher</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Maraganore</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Lieberman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. 2007. Interfering with disease: a progress report on siRNA‐based therapeutics. Nat Rev Drug Discov 6:443–453.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>443</start><end>453</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Rev Drug Discov</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>443</start><end>453</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Analysis of gene function in somatic mammalian cells using small interfering RNAs</title></titleInfo><name type="personal"><namePart type="given">SM</namePart><namePart type="family">Elbashir</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Harborth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Weber</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Tuschl</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Elbashir SM, Harborth J, Weber K, Tuschl T. 2002. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26:199–213.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>199</start><end>213</end></extent></part><relatedItem type="host"><titleInfo><title>Methods</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>199</start><end>213</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production</title></titleInfo><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Emeny</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MJ.</namePart><namePart type="family">Morgan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Emeny JM, Morgan MJ. 1979. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol 43:247–252.</note><part><date>1979</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>247</start><end>252</end></extent></part><relatedItem type="host"><titleInfo><title>J Gen Virol</title></titleInfo><part><date>1979</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>247</start><end>252</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Structure‐function analysis of the soluble glycoprotein, sGP, of Ebola virus</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Falzarano</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O</namePart><namePart type="family">Krokhin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V</namePart><namePart type="family">Wahl‐Jensen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Seebach</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Wolf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HJ</namePart><namePart type="family">Schnittler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Feldmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Falzarano D, Krokhin O, Wahl‐Jensen V, Seebach J, Wolf K, Schnittler HJ, Feldmann H. 2006. Structure‐function analysis of the soluble glycoprotein, sGP, of Ebola virus. Chembiochem 7:1605–1611.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>1605</start><end>1611</end></extent></part><relatedItem type="host"><titleInfo><title>Chembiochem</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>1605</start><end>1611</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Marburg hemorrhagic fever—the forgotten cousin strikes</title></titleInfo><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Feldmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Feldmann H. 2006. Marburg hemorrhagic fever—the forgotten cousin strikes. N Engl J Med 355:866–869.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>355</number></detail><extent unit="pages"><start>866</start><end>869</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>355</number></detail><extent unit="pages"><start>866</start><end>869</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double‐stranded RNA‐dependent protein kinase PKR</title></titleInfo><name type="personal"><namePart type="given">Z</namePart><namePart type="family">Feng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Cerveny</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Z</namePart><namePart type="family">Yan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">He</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Feng Z, Cerveny M, Yan Z, He B. 2007. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double‐stranded RNA‐dependent protein kinase PKR. J Virol 81:182–192.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>81</number></detail><extent unit="pages"><start>182</start><end>192</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>81</number></detail><extent unit="pages"><start>182</start><end>192</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Inhibition of Marburg virus protein expression and viral release by RNA interference</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Fowler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Bamberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Moller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HD</namePart><namePart type="family">Klenk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TF</namePart><namePart type="family">Meyer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Becker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Rudel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fowler T, Bamberg S, Moller P, Klenk HD, Meyer TF, Becker S, Rudel T. 2005. Inhibition of Marburg virus protein expression and viral release by RNA interference. J Gen Virol 86:1181–1188.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>86</number></detail><extent unit="pages"><start>1181</start><end>1188</end></extent></part><relatedItem type="host"><titleInfo><title>J Gen Virol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>86</number></detail><extent unit="pages"><start>1181</start><end>1188</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Innate immune defense through RNA interference</title></titleInfo><name type="personal"><namePart type="given">JH</namePart><namePart type="family">Fritz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SE</namePart><namePart type="family">Girardin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DJ.</namePart><namePart type="family">Philpott</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fritz JH, Girardin SE, Philpott DJ. 2006. Innate immune defense through RNA interference. Sci STKE 2006:pe27.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>2006</number></detail><extent unit="pages"><start>pe27</start></extent></part><relatedItem type="host"><titleInfo><title>Sci STKE</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>2006</number></detail><extent unit="pages"><start>pe27</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Fomivirsen: clinical pharmacology and potential drug interactions</title></titleInfo><name type="personal"><namePart type="given">RS</namePart><namePart type="family">Geary</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SP</namePart><namePart type="family">Henry</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LR.</namePart><namePart type="family">Grillone</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Geary RS, Henry SP, Grillone LR. 2002. Fomivirsen: clinical pharmacology and potential drug interactions. Clin Pharmacokinet 41:255–260.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>255</start><end>260</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacokinet</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>255</start><end>260</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection</title></titleInfo><name type="personal"><namePart type="given">TW</namePart><namePart type="family">Geisbert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LE</namePart><namePart type="family">Hensley</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Larsen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HA</namePart><namePart type="family">Young</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DS</namePart><namePart type="family">Reed</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JB</namePart><namePart type="family">Geisbert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DP</namePart><namePart type="family">Scott</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Kagan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PB</namePart><namePart type="family">Jahrling</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KJ.</namePart><namePart type="family">Davis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, Scott DP, Kagan E, Jahrling PB, Davis KJ. 2003a. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163:2347–2370.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>163</number></detail><extent unit="pages"><start>2347</start><end>2370</end></extent></part><relatedItem type="host"><titleInfo><title>Am J Pathol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>163</number></detail><extent unit="pages"><start>2347</start><end>2370</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus‐induced cytolysis of endothelial cells</title></titleInfo><name type="personal"><namePart type="given">TW</namePart><namePart type="family">Geisbert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HA</namePart><namePart type="family">Young</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PB</namePart><namePart type="family">Jahrling</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KJ</namePart><namePart type="family">Davis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Larsen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Kagan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LE.</namePart><namePart type="family">Hensley</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, Hensley LE. 2003b. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus‐induced cytolysis of endothelial cells. Am J Pathol 163:2371–2382.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>163</number></detail><extent unit="pages"><start>2371</start><end>2382</end></extent></part><relatedItem type="host"><titleInfo><title>Am J Pathol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>163</number></detail><extent unit="pages"><start>2371</start><end>2382</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference</title></titleInfo><name type="personal"><namePart type="given">TW</namePart><namePart type="family">Geisbert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LE</namePart><namePart type="family">Hensley</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Kagan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EZ</namePart><namePart type="family">Yu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JB</namePart><namePart type="family">Geisbert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Daddario‐DiCaprio</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EA</namePart><namePart type="family">Fritz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PB</namePart><namePart type="family">Jahrling</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">McClintock</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JR</namePart><namePart type="family">Phelps</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario‐DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR and others. 2006. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 193:1650–1657.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>193</number></detail><extent unit="pages"><start>1650</start><end>1657</end></extent></part><relatedItem type="host"><titleInfo><title>J Infect Dis</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>193</number></detail><extent unit="pages"><start>1650</start><end>1657</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Grimm</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KL</namePart><namePart type="family">Streetz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CL</namePart><namePart type="family">Jopling</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">TA</namePart><namePart type="family">Storm</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Pandey</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CR</namePart><namePart type="family">Davis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Marion</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Salazar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MA.</namePart><namePart type="family">Kay</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA. 2006. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537–541.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>441</number></detail><extent unit="pages"><start>537</start><end>541</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>441</number></detail><extent unit="pages"><start>537</start><end>541</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>The FDA animal efficacy rule and biodefense</title></titleInfo><name type="personal"><namePart type="given">GK</namePart><namePart type="family">Gronvall</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Trent</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Borio</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Brey</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Nagao</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gronvall GK, Trent D, Borio L, Brey R, Nagao L. 2007. The FDA animal efficacy rule and biodefense. Nat Biotechnol 25:1084–1087.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1084</start><end>1087</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Biotechnol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1084</start><end>1087</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>The ecology of Ebola virus</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Groseth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Feldmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JE.</namePart><namePart type="family">Strong</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Groseth A, Feldmann H, Strong JE. 2007a. The ecology of Ebola virus. Trends Microbiol 15:408–416.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>408</start><end>416</end></extent></part><relatedItem type="host"><titleInfo><title>Trends Microbiol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>408</start><end>416</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Groseth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Hoenen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JB</namePart><namePart type="family">Alimonti</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Zielecki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Ebihara</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Theriault</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">U</namePart><namePart type="family">Stroher</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Becker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Feldmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Groseth A, Hoenen T, Alimonti JB, Zielecki F, Ebihara H, Theriault S, Stroher U, Becker S, Feldmann H. 2007b. In vitro evaluation of antisense RNA efficacy against filovirus infection, by use of reverse genetics. J Infect Dis 196 (Suppl 2):S382–S389.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>196</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 2</number></detail><extent unit="pages"><start>S382</start><end>389</end></extent></part><relatedItem type="host"><titleInfo><title>J Infect Dis</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>196</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 2</number></detail><extent unit="pages"><start>S382</start><end>389</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>The Ebola virus VP35 protein is a suppressor of RNA silencing</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Haasnoot</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W</namePart><namePart type="family">de Vries</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EJ</namePart><namePart type="family">Geutjes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Prins</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">de Haan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Berkhout</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Haasnoot J, de Vries W, Geutjes EJ, Prins M, de Haan P, Berkhout B. 2007. The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog 3:e86.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>e86</start></extent></part><relatedItem type="host"><titleInfo><title>PLoS Pathog</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>e86</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Filovirus assembly and budding</title></titleInfo><name type="personal"><namePart type="given">B</namePart><namePart type="family">Hartlieb</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">W.</namePart><namePart type="family">Weissenhorn</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hartlieb B, Weissenhorn W. 2006. Filovirus assembly and budding. Virology 344:64–70.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>344</number></detail><extent unit="pages"><start>64</start><end>70</end></extent></part><relatedItem type="host"><titleInfo><title>Virology</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>344</number></detail><extent unit="pages"><start>64</start><end>70</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>Inhibition of IRF‐3 activation by VP35 is critical for the high virulence of Ebola virus</title></titleInfo><name type="personal"><namePart type="given">AL</namePart><namePart type="family">Hartman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BH</namePart><namePart type="family">Bird</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JS</namePart><namePart type="family">Towner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ZA</namePart><namePart type="family">Antoniadou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SR</namePart><namePart type="family">Zaki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ST.</namePart><namePart type="family">Nichol</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hartman AL, Bird BH, Towner JS, Antoniadou ZA, Zaki SR, Nichol ST. 2008. Inhibition of IRF‐3 activation by VP35 is critical for the high virulence of Ebola virus. J Virol 82:2699–2704.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>82</number></detail><extent unit="pages"><start>2699</start><end>2704</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>82</number></detail><extent unit="pages"><start>2699</start><end>2704</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>DEQOR: a web‐based tool for the design and quality control of siRNAs</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Henschel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Buchholz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Habermann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Henschel A, Buchholz F, Habermann B. 2004. DEQOR: a web‐based tool for the design and quality control of siRNAs. Nucleic Acids Res 32:W113–W120.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>W113</start><end>W120</end></extent></part><relatedItem type="host"><titleInfo><title>Nucleic Acids Res</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>W113</start><end>W120</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit29"><titleInfo><title>Ebola virus: unravelling pathogenesis to combat a deadly disease</title></titleInfo><name type="personal"><namePart type="given">T</namePart><namePart type="family">Hoenen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Groseth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Falzarano</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Feldmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hoenen T, Groseth A, Falzarano D, Feldmann H. 2006. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med 12:206–215.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>206</start><end>215</end></extent></part><relatedItem type="host"><titleInfo><title>Trends Mol Med</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>206</start><end>215</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit30"><titleInfo><title>The assembly of Ebola virus nucleocapsid requires virion‐associated proteins 35 and 24 and posttranslational modification of nucleoprotein</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Huang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Xu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Sun</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GJ.</namePart><namePart type="family">Nabel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Huang Y, Xu L, Sun Y, Nabel GJ. 2002. The assembly of Ebola virus nucleocapsid requires virion‐associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell 10:307–316.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>307</start><end>316</end></extent></part><relatedItem type="host"><titleInfo><title>Mol Cell</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>307</start><end>316</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit31"><titleInfo><title>Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Jaax</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Jahrling</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Geisbert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Geisbert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Steele</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">McKee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Nagley</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Johnson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Jaax</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Peters</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jaax N, Jahrling P, Geisbert T, Geisbert J, Steele K, McKee K, Nagley D, Johnson E, Jaax G, Peters C. 1995. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 346:1669–1671.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>346</number></detail><extent unit="pages"><start>1669</start><end>1671</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>346</number></detail><extent unit="pages"><start>1669</start><end>1671</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit32"><titleInfo><title>Filovirus budding</title></titleInfo><name type="personal"><namePart type="given">LD</namePart><namePart type="family">Jasenosky</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Kawaoka</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jasenosky LD, Kawaoka Y. 2004. Filovirus budding. Virus Res 106:181–188.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>181</start><end>188</end></extent></part><relatedItem type="host"><titleInfo><title>Virus Res</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>181</start><end>188</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit33"><titleInfo><title>Effective RNAi‐mediated gene silencing without interruption of the endogenous microRNA pathway</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">John</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Constien</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Akinc</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Goldberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YA</namePart><namePart type="family">Moon</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Spranger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Hadwiger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Soutschek</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HP</namePart><namePart type="family">Vornlocher</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Manoharan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Stoffel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Langer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DG</namePart><namePart type="family">Anderson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JD</namePart><namePart type="family">Horton</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V</namePart><namePart type="family">Koteliansky</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Bumcrot</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">John M, Constien R, Akinc A, Goldberg M, Moon YA, Spranger M, Hadwiger P, Soutschek J, Vornlocher HP, Manoharan M, Stoffel M, Langer R, Anderson DG, Horton JD, Koteliansky V, Bumcrot D. 2007. Effective RNAi‐mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 449:745–747.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>449</number></detail><extent unit="pages"><start>745</start><end>747</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>449</number></detail><extent unit="pages"><start>745</start><end>747</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit34"><titleInfo><title>Transvascular delivery of small interfering RNA to the central nervous system</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Kumar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Wu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JL</namePart><namePart type="family">McBride</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KE</namePart><namePart type="family">Jung</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MH</namePart><namePart type="family">Kim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BL</namePart><namePart type="family">Davidson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SK</namePart><namePart type="family">Lee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Shankar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.</namePart><namePart type="family">Manjunath</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, Lee SK, Shankar P, Manjunath N. 2007. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448:39–43.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>448</number></detail><extent unit="pages"><start>39</start><end>43</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>448</number></detail><extent unit="pages"><start>39</start><end>43</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit35"><titleInfo><title>Immense promises for tiny molecules: uncovering miRNA functions</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">le Sage</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Agami</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">le Sage C, Agami R. 2006. Immense promises for tiny molecules: uncovering miRNA functions. Cell Cycle 5:1415–1421.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>1415</start><end>1421</end></extent></part><relatedItem type="host"><titleInfo><title>Cell Cycle</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>1415</start><end>1421</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit36"><titleInfo><title>The C. elegans heterochronic gene lin‐4 encodes small RNAs with antisense complementarity to lin‐14</title></titleInfo><name type="personal"><namePart type="given">RC</namePart><namePart type="family">Lee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RL</namePart><namePart type="family">Feinbaum</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V.</namePart><namePart type="family">Ambros</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lee RC, Feinbaum RL, Ambros V. 1993. The C. elegans heterochronic gene lin‐4 encodes small RNAs with antisense complementarity to lin‐14. Cell 75:843–854.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>843</start><end>854</end></extent></part><relatedItem type="host"><titleInfo><title>Cell</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>843</start><end>854</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit37"><titleInfo><title>siRNA—getting the message out</title></titleInfo><name type="personal"><namePart type="given">SH</namePart><namePart type="family">Lee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PJ.</namePart><namePart type="family">Sinko</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lee SH, Sinko PJ. 2006. siRNA—getting the message out. Eur J Pharm Sci 27:401–410.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>401</start><end>410</end></extent></part><relatedItem type="host"><titleInfo><title>Eur J Pharm Sci</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>401</start><end>410</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit38"><titleInfo><title>The nuclear RNase III Drosha initiates microRNA processing</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Lee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Ahn</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Han</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Choi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Kim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Yim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Lee</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Provost</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O</namePart><namePart type="family">Radmark</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Kim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VN</namePart><namePart type="family">Kim</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN. 2003. The nuclear RNase III Drosha initiates microRNA processing. Nature 425:415–419.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>425</number></detail><extent unit="pages"><start>415</start><end>419</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>425</number></detail><extent unit="pages"><start>415</start><end>419</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit39"><titleInfo><title>Marburg and Ebola viruses as aerosol threats</title></titleInfo><name type="personal"><namePart type="given">EK</namePart><namePart type="family">Leffel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DS.</namePart><namePart type="family">Reed</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Leffel EK, Reed DS. 2004. Marburg and Ebola viruses as aerosol threats. Biosecur Bioterror 2:186–191.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>186</start><end>191</end></extent></part><relatedItem type="host"><titleInfo><title>Biosecur Bioterror</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>186</start><end>191</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit40"><titleInfo><title>Pathogenesis of filoviral haemorrhagic fevers</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Mahanty</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Bray</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mahanty S, Bray M. 2004. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4:487–498.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>487</start><end>498</end></extent></part><relatedItem type="host"><titleInfo><title>Lancet Infect Dis</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>487</start><end>498</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit41"><titleInfo><title>Comprehensive analysis of ebola virus GP1 in viral entry</title></titleInfo><name type="personal"><namePart type="given">B</namePart><namePart type="family">Manicassamy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Jiang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Rong</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Manicassamy B, Wang J, Jiang H, Rong L. 2005. Comprehensive analysis of ebola virus GP1 in viral entry. J Virol 79:4793–4805.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>4793</start><end>4805</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>4793</start><end>4805</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit42"><titleInfo><title>Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Muhlberger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Weik</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VE</namePart><namePart type="family">Volchkov</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HD</namePart><namePart type="family">Klenk</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Becker</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Muhlberger E, Weik M, Volchkov VE, Klenk HD, Becker S. 1999. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol 73:2333–2342.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>2333</start><end>2342</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>2333</start><end>2342</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit43"><titleInfo><title>Filovirus replication and transcription</title></titleInfo><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Muhlberger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Muhlberger E. 2007. Filovirus replication and transcription. Future Virol 2:205–215.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>205</start><end>215</end></extent></part><relatedItem type="host"><titleInfo><title>Future Virol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>205</start><end>215</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit44"><titleInfo><title>Technology evaluation: fomivirsen. Isis Pharmaceuticals Inc/CIBA vision</title></titleInfo><name type="personal"><namePart type="given">RM.</namePart><namePart type="family">Orr</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Orr RM. 2001. Technology evaluation: fomivirsen. Isis Pharmaceuticals Inc/CIBA vision. Curr Opin Mol Ther 3:288–294.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>288</start><end>294</end></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Mol Ther</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>288</start><end>294</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit45"><titleInfo><title>On the art of identifying effective and specific siRNAs</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Pei</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.</namePart><namePart type="family">Tuschl</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pei Y, Tuschl T. 2006. On the art of identifying effective and specific siRNAs. Nat Methods 3:670–676.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>670</start><end>676</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Methods</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>670</start><end>676</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit46"><titleInfo><title>Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation</title></titleInfo><name type="personal"><namePart type="given">SP</namePart><namePart type="family">Reid</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LW</namePart><namePart type="family">Leung</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AL</namePart><namePart type="family">Hartman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O</namePart><namePart type="family">Martinez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ML</namePart><namePart type="family">Shaw</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Carbonnelle</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VE</namePart><namePart type="family">Volchkov</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ST</namePart><namePart type="family">Nichol</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CF.</namePart><namePart type="family">Basler</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, Volchkov VE, Nichol ST, Basler CF. 2006. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 80:5156–5167.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>5156</start><end>5167</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>5156</start><end>5167</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit47"><titleInfo><title>The 21‐nucleotide let‐7 RNA regulates developmental timing in Caenorhabditis elegans</title></titleInfo><name type="personal"><namePart type="given">BJ</namePart><namePart type="family">Reinhart</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FJ</namePart><namePart type="family">Slack</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Basson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AE</namePart><namePart type="family">Pasquinelli</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Bettinger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AE</namePart><namePart type="family">Rougvie</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HR</namePart><namePart type="family">Horvitz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Ruvkun</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G. 2000. The 21‐nucleotide let‐7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403:901–906.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>403</number></detail><extent unit="pages"><start>901</start><end>906</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>403</number></detail><extent unit="pages"><start>901</start><end>906</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit48"><titleInfo><title>sIR: siRNA Information Resource, a web‐based tool for siRNA sequence design and analysis and an open access siRNA database</title></titleInfo><name type="personal"><namePart type="given">JK</namePart><namePart type="family">Shah</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HR</namePart><namePart type="family">Garner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MA</namePart><namePart type="family">White</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DS</namePart><namePart type="family">Shames</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JD.</namePart><namePart type="family">Minna</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shah JK, Garner HR, White MA, Shames DS, Minna JD. 2007. sIR: siRNA Information Resource, a web‐based tool for siRNA sequence design and analysis and an open access siRNA database. BMC Bioinformatics 8:178.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>178</start></extent></part><relatedItem type="host"><titleInfo><title>BMC Bioinformatics</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>178</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit49"><titleInfo><title>RNA interference and innate immunity</title></titleInfo><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Sioud</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sioud M. 2007. RNA interference and innate immunity. Adv Drug Deliv Rev 59:153–163.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>153</start><end>163</end></extent></part><relatedItem type="host"><titleInfo><title>Adv Drug Deliv Rev</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>153</start><end>163</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit50"><titleInfo><title>Assembly and function of RNA silencing complexes</title></titleInfo><name type="personal"><namePart type="given">EJ.</namePart><namePart type="family">Sontheimer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sontheimer EJ. 2005. Assembly and function of RNA silencing complexes. Nat Rev Mol Cell Biol 6:127–138.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>127</start><end>138</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Rev Mol Cell Biol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>127</start><end>138</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit51"><titleInfo><title>Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses</title></titleInfo><name type="personal"><namePart type="given">KB</namePart><namePart type="family">Spurgers</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Sharkey</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KL</namePart><namePart type="family">Warfield</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Bavari</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Spurgers KB, Sharkey CM, Warfield KL, Bavari S. 2008. Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 78:26–36.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>26</start><end>36</end></extent></part><relatedItem type="host"><titleInfo><title>Antiviral Res</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>26</start><end>36</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit52"><titleInfo><title>Ebola virus glycoprotein toxicity is mediated by a dynamin‐dependent protein‐trafficking pathway</title></titleInfo><name type="personal"><namePart type="given">NJ</namePart><namePart type="family">Sullivan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Peterson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">ZY</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WP</namePart><namePart type="family">Kong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Duckers</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Nabel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GJ.</namePart><namePart type="family">Nabel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sullivan NJ, Peterson M, Yang ZY, Kong WP, Duckers H, Nabel E, Nabel GJ. 2005. Ebola virus glycoprotein toxicity is mediated by a dynamin‐dependent protein‐trafficking pathway. J Virol 79:547–553.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>547</start><end>553</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>547</start><end>553</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit53"><titleInfo><title>An Ebola epidemic simmers in Africa: in remote region, outbreak shows staying power</title></titleInfo><name type="personal"><namePart type="given">PD.</namePart><namePart type="family">Thacker</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Thacker PD. 2003. An Ebola epidemic simmers in Africa: in remote region, outbreak shows staying power. JAMA 290:317–319.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>290</number></detail><extent unit="pages"><start>317</start><end>319</end></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>290</number></detail><extent unit="pages"><start>317</start><end>319</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit54"><titleInfo><title>Rescue of Ebola virus from cDNA using heterologous support proteins</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Theriault</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Groseth</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Neumann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Kawaoka</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Feldmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Theriault S, Groseth A, Neumann G, Kawaoka Y, Feldmann H. 2004. Rescue of Ebola virus from cDNA using heterologous support proteins. Virus Res 106:43–50.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>43</start><end>50</end></extent></part><relatedItem type="host"><titleInfo><title>Virus Res</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>43</start><end>50</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit55"><titleInfo><title>Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region</title></titleInfo><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Wilson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CD.</namePart><namePart type="family">Richardson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wilson JA, Richardson CD. 2005. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J Virol 79:7050–7058.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>7050</start><end>7058</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>7050</start><end>7058</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit56"><titleInfo><title>Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury</title></titleInfo><name type="personal"><namePart type="given">ZY</namePart><namePart type="family">Yang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HJ</namePart><namePart type="family">Duckers</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NJ</namePart><namePart type="family">Sullivan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Sanchez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EG</namePart><namePart type="family">Nabel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GJ.</namePart><namePart type="family">Nabel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. 2000. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 6:886–889.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>886</start><end>889</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Med</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>886</start><end>889</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit57"><titleInfo><title>The microRNA: overview of the RNA gene that modulates gene functions</title></titleInfo><name type="personal"><namePart type="given">SY</namePart><namePart type="family">Ying</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DC</namePart><namePart type="family">Chang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JD</namePart><namePart type="family">Miller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SL.</namePart><namePart type="family">Lin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ying SY, Chang DC, Miller JD, Lin SL. 2006. The microRNA: overview of the RNA gene that modulates gene functions. Methods Mol Biol 342:1–18.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>342</number></detail><extent unit="pages"><start>1</start><end>18</end></extent></part><relatedItem type="host"><titleInfo><title>Methods Mol Biol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>342</number></detail><extent unit="pages"><start>1</start><end>18</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit58"><titleInfo><title>Immunopathology of highly virulent pathogens: insights from Ebola virus</title></titleInfo><name type="personal"><namePart type="given">CA</namePart><namePart type="family">Zampieri</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NJ</namePart><namePart type="family">Sullivan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GJ.</namePart><namePart type="family">Nabel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zampieri CA, Sullivan NJ, Nabel GJ. 2007. Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat Immunol 8:1159–1164.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>1159</start><end>1164</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Immunol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>1159</start><end>1164</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit59"><titleInfo><title>Development of resistance to RNAi in mammalian cells</title></titleInfo><name type="personal"><namePart type="given">ZM</namePart><namePart type="family">Zheng</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Tang</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Tao</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zheng ZM, Tang S, Tao M. 2005. Development of resistance to RNAi in mammalian cells. Ann NY Acad Sci 1058:105–118.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>1058</number></detail><extent unit="pages"><start>105</start><end>118</end></extent></part><relatedItem type="host"><titleInfo><title>Ann NY Acad Sci</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>1058</number></detail><extent unit="pages"><start>105</start><end>118</end></extent></part></relatedItem></relatedItem><identifier type="istex">8F695DC3706B8D0E196621EAD7C011884B3CAB57</identifier><identifier type="ark">ark:/67375/WNG-KZH1CJ3C-S</identifier><identifier type="DOI">10.1002/ddr.20302</identifier><identifier type="ArticleID">DDR20302</identifier><accessCondition type="use and reproduction" contentType="copyright">Published 2009 Wiley‐Liss, Inc.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-14</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-KZH1CJ3C-S/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001588 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001588 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:8F695DC3706B8D0E196621EAD7C011884B3CAB57
|texte= Toward RNA interference‐based therapy for filovirus infections
}}
| This area was generated with Dilib version V0.6.33. |  |